-- 根據週一提交給東京證券交易所的文件顯示，PeptiDream（東京證券交易所代碼：4587）宣布，其合作夥伴旭化成製藥已啟動其勝肽平台發現的TNFR1抑制劑AK1940的I期臨床試驗。 該公司表示，該候選藥物針對自體免疫疾病，並在臨床前研究中顯示出療效。 PeptiDream將獲得一筆里程碑付款，並有資格獲得與研發和銷售相關的後續付款和特許權使用費。
Related Articles
Asia
ZTT's Q1 Profit Jumps 46%, Revenue Climbs 35%; Shares Up 10%
Jiangsu Zhongtian Technology (SHA:600522), or ZTT, said its net profit attributable to shareholders in the first quarter jumped 46% to nearly 919 million yuan from 627.6 million yuan, according to a Saturday filing on the Shanghai bourse.The Chinese communication products manufacturer's shares soared 10% in late-morning trade Monday.Earnings per share increased 47% year on year to 0.270 yuan from 0.184 yuan.Operating revenue climbed 35% to 13.1 billion yuan from 9.76 billion yuan in the previous year.
$SHA:600522
Asia
Century City, Paliburg, Regal Transfer Sale of Regal Oriental Hotel to Centaline JV
Century City (HKG:0355), Paliburg (HKG:0617), and Regal (HKG:0078) said they transferred the sale agreement involving the disposal of Regal Oriental Hotel to a Centaline Strategic Investments joint venture, according to a Hong Kong bourse filing Friday.Shares of Paliburg fell over 2% in morning trade on Monday, while Century City was up 1%.The firms had agreed to dispose of Regal Oriental Hotel at a property value of HK$1.52 billion, but said they could not reach a formal agreement with the purchaser, previously identified as Blue Sky Properties, an investment vehicle ultimately owned by Centaline Strategic Investments.Instead, the firms will now sell the property to Goldenridge Worldwide, a joint venture of Centaline and investor Liu De Ye, Ching.All other terms of the original sale agreement remain unchanged, the firms said.
$HKG:0078$HKG:0355$HKG:0617
Asia
CNPC Capital's 2025 Profit Falls 8%, Revenue Drops 13%
CNPC Capital's (SHE:000617) net profit attributable to shareholders in 2025 slipped 8% to 4.30 billion yuan, or 0.34 yuan per share, according to a Saturday filing on the Shenzhen bourse.The attributable profit a year earlier was 4.65 billion yuan, or 0.37 yuan per share.Operating revenue dropped 13% to 33.8 billion yuan from 39.0 billion yuan in the previous year.
$SHE:000617